Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • IT / Health Venture
    • UE LifeSciences in...

    UE LifeSciences in distribution partnership with GE Healthcare

    Written by Ruby Khatun Khatun Published On 2017-11-12T10:15:52+05:30  |  Updated On 18 Aug 2021 2:56 PM IST

    Bengaluru: UE LifeSciences Inc, a USA-India based med-tech startup, announced a distribution partnership with GE Healthcare to commercialize its iBreastExam (iBE) in countries across South Asia and Africa.


    The partnership brings together UE LifeSciences' skills to design and develop mobile health innovations, and GE Healthcare's sales, marketing and distribution expertise in these markets to enable early detection of breast cancer in the developing world, the company officials said.
    "iBreastExam can truly create access where none exists right now across our partnership geography," UELifeSciences founder and CEO Mihir Shah told reporters here.

    Over 75,000 women have been screened in the country with the help of iBreastExam and 100-plus breast cancer cases identified in partnership with 40-plus private healthcare, government institutions, non-profit and CSR initiatives, he said.


    UE LifeSciences said iBreastExam is an innovative, validated mobile breast health solution designed for use by primary health workers, obstetricians and gynaecologists to identify breast abnormalities in healthy, asymptomatic women during a routine health checkup.

    Being a radiation-free and painless test further makes iBE suitable to women at primary care locations such as a doctor's clinic, community health centers, health camps or a hospital's out-patient department, he said.

    The partnership provides a significant opportunity to commercially scale-up iBE across India, South Asia, Africa and South-East Asia and improves breast cancer-related outcomes in these regions, GE Healthcare SustainableHealthcare Solutions President and CEO Terri Bresenham said.

    "With the wealth of engineering talent that we have in this country, with the gap in healthcare system being out of reach, particularly for the rural population, we need to play a different role," she said.

    "So our goal is to help bring startup companies like UE LifeSciences together with what we can provide - scaled distribution, service and support model across vast regions of the world," she added.

    iBE is a "Made in India" device developed by ateam of 20-plus scientists, engineers and clinicians with USD1.3 millionin grant funding from Pennsylvania Department of Health (CURE Grant), University City Science Center (QED & DHA), Drexel University (Coulter Programme) and Unitus Seed Fund(StartHealth grant).

    It is currently commercially available in India, Myanmar, and Botswana.

    The project has been mentored and invested by Kiran Mazumdar-Shaw of Biocon, Dr. Ranjan Pai of Manipal Education and Medical Group and Unitus Seed Fund, a social impact investor in affordable healthcare innovations.

    Stressing on the need to "downstage" cancer, Mazumdar-Shaw said it is a difficult task as most people only go for diagnosis when it is too late.

    Stating that innovations like iBreastExam should be made a standard of care, she said "The moment you downstage cancer and you detect it early it converts from cancer care to cancer cure. I think governments also need to adopt this because when we look into diagnosis and diagnostics that is about preventive healthcare."

    Pointing out that today more lives were being lost to breast cancer in India than any other country in the world, Shah said it is not only the most commonly occurring cancer in India, it occurs in one in 28 women over their life time, and of that half the cases were in women under 50 years of age.

    He said survival rate was about 52 percent that means India is losing one out of two women to breast cancer, which is in contrast to the US where nine in ten survive.

    Three published clinical validation studies showed 83-86 percent sensitivity and 88-94 percent specificity for iBE to detect clinically relevant breast abnormalities, company officials claimed.
    AfricaBioconBotswanabreast abnormalitiesbreast cancerclinical validationcommercializedistributionDr Ranjan PaiGE HealthcareiBreastExamIndiaKiran Mazumdar ShawManipal EducationMihir Shahmobile health innovationsMyanmarpartnershipprivate healthcareSouth AsiaTerri BresenhamUE LifeSciences
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok